nodes	percent_of_prediction	percent_of_DWPC	metapath
Alprostadil—SLCO2B1—Montelukast—chronic obstructive pulmonary disease	0.483	1	CbGbCtD
Alprostadil—PTGIR—pulmonary artery—chronic obstructive pulmonary disease	0.0335	0.33	CbGeAlD
Alprostadil—PTGER2—trachea—chronic obstructive pulmonary disease	0.00712	0.07	CbGeAlD
Alprostadil—PTGIR—respiratory system—chronic obstructive pulmonary disease	0.00564	0.0555	CbGeAlD
Alprostadil—PTGER2—lung—chronic obstructive pulmonary disease	0.00511	0.0503	CbGeAlD
Alprostadil—PTGIR—connective tissue—chronic obstructive pulmonary disease	0.00497	0.0488	CbGeAlD
Alprostadil—SLCO2A1—respiratory system—chronic obstructive pulmonary disease	0.00493	0.0485	CbGeAlD
Alprostadil—PTGIR—smooth muscle tissue—chronic obstructive pulmonary disease	0.00454	0.0447	CbGeAlD
Alprostadil—SLCO3A1—bronchus—chronic obstructive pulmonary disease	0.0041	0.0403	CbGeAlD
Alprostadil—SLCO2A1—bronchus—chronic obstructive pulmonary disease	0.00406	0.0399	CbGeAlD
Alprostadil—ABCC5—bronchus—chronic obstructive pulmonary disease	0.00371	0.0365	CbGeAlD
Alprostadil—SLCO2A1—trachea—chronic obstructive pulmonary disease	0.00364	0.0358	CbGeAlD
Alprostadil—SLCO2B1—respiratory system—chronic obstructive pulmonary disease	0.00353	0.0347	CbGeAlD
Alprostadil—PTGIR—lung—chronic obstructive pulmonary disease	0.003	0.0295	CbGeAlD
Alprostadil—SLCO3A1—lung—chronic obstructive pulmonary disease	0.00264	0.026	CbGeAlD
Alprostadil—SLCO2A1—lung—chronic obstructive pulmonary disease	0.00262	0.0258	CbGeAlD
Alprostadil—ABCC4—bronchus—chronic obstructive pulmonary disease	0.00257	0.0253	CbGeAlD
Alprostadil—ABCC5—lung—chronic obstructive pulmonary disease	0.00239	0.0236	CbGeAlD
Alprostadil—SLCO2B1—lung—chronic obstructive pulmonary disease	0.00187	0.0184	CbGeAlD
Alprostadil—ABCC4—lung—chronic obstructive pulmonary disease	0.00166	0.0163	CbGeAlD
Alprostadil—Hyperglycaemia—Arformoterol—chronic obstructive pulmonary disease	0.000875	0.0031	CcSEcCtD
Alprostadil—Hyperglycaemia—Formoterol—chronic obstructive pulmonary disease	0.000875	0.0031	CcSEcCtD
Alprostadil—Nervousness—Aminophylline—chronic obstructive pulmonary disease	0.000863	0.00305	CcSEcCtD
Alprostadil—Abdominal pain—Roflumilast—chronic obstructive pulmonary disease	0.000859	0.00304	CcSEcCtD
Alprostadil—Acute coronary syndrome—Arformoterol—chronic obstructive pulmonary disease	0.000853	0.00302	CcSEcCtD
Alprostadil—Acute coronary syndrome—Formoterol—chronic obstructive pulmonary disease	0.000853	0.00302	CcSEcCtD
Alprostadil—Upper respiratory tract infection—Salbutamol—chronic obstructive pulmonary disease	0.000851	0.00301	CcSEcCtD
Alprostadil—Myocardial infarction—Formoterol—chronic obstructive pulmonary disease	0.000848	0.003	CcSEcCtD
Alprostadil—Myocardial infarction—Arformoterol—chronic obstructive pulmonary disease	0.000848	0.003	CcSEcCtD
Alprostadil—Urinary tract infection—Arformoterol—chronic obstructive pulmonary disease	0.000841	0.00297	CcSEcCtD
Alprostadil—Urinary tract infection—Formoterol—chronic obstructive pulmonary disease	0.000841	0.00297	CcSEcCtD
Alprostadil—Hyperglycaemia—Salbutamol—chronic obstructive pulmonary disease	0.000826	0.00292	CcSEcCtD
Alprostadil—Haematuria—Formoterol—chronic obstructive pulmonary disease	0.000825	0.00292	CcSEcCtD
Alprostadil—Haematuria—Arformoterol—chronic obstructive pulmonary disease	0.000825	0.00292	CcSEcCtD
Alprostadil—Sinusitis—Arformoterol—chronic obstructive pulmonary disease	0.000812	0.00287	CcSEcCtD
Alprostadil—Sinusitis—Formoterol—chronic obstructive pulmonary disease	0.000812	0.00287	CcSEcCtD
Alprostadil—Back pain—Tiotropium—chronic obstructive pulmonary disease	0.00081	0.00287	CcSEcCtD
Alprostadil—Sinusitis—Montelukast—chronic obstructive pulmonary disease	0.000795	0.00281	CcSEcCtD
Alprostadil—Urinary tract infection—Salbutamol—chronic obstructive pulmonary disease	0.000794	0.00281	CcSEcCtD
Alprostadil—Fungal infection—Prednisone—chronic obstructive pulmonary disease	0.000788	0.00279	CcSEcCtD
Alprostadil—Asthenia—Roflumilast—chronic obstructive pulmonary disease	0.00078	0.00276	CcSEcCtD
Alprostadil—Haematuria—Salbutamol—chronic obstructive pulmonary disease	0.000779	0.00275	CcSEcCtD
Alprostadil—Rhinitis—Formoterol—chronic obstructive pulmonary disease	0.000779	0.00275	CcSEcCtD
Alprostadil—Rhinitis—Arformoterol—chronic obstructive pulmonary disease	0.000779	0.00275	CcSEcCtD
Alprostadil—Pharyngitis—Formoterol—chronic obstructive pulmonary disease	0.000771	0.00273	CcSEcCtD
Alprostadil—Pharyngitis—Arformoterol—chronic obstructive pulmonary disease	0.000771	0.00273	CcSEcCtD
Alprostadil—Convulsion—Aminophylline—chronic obstructive pulmonary disease	0.00077	0.00272	CcSEcCtD
Alprostadil—Sinusitis—Salbutamol—chronic obstructive pulmonary disease	0.000766	0.00271	CcSEcCtD
Alprostadil—Rhinitis—Montelukast—chronic obstructive pulmonary disease	0.000763	0.0027	CcSEcCtD
Alprostadil—Urethral disorder—Arformoterol—chronic obstructive pulmonary disease	0.000761	0.00269	CcSEcCtD
Alprostadil—Urethral disorder—Formoterol—chronic obstructive pulmonary disease	0.000761	0.00269	CcSEcCtD
Alprostadil—Ecchymosis—Prednisolone—chronic obstructive pulmonary disease	0.000757	0.00268	CcSEcCtD
Alprostadil—Hypoaesthesia—Montelukast—chronic obstructive pulmonary disease	0.000757	0.00268	CcSEcCtD
Alprostadil—ABCC5—NRF2 pathway—GCLC—chronic obstructive pulmonary disease	0.000755	0.00569	CbGpPWpGaD
Alprostadil—Pharyngitis—Montelukast—chronic obstructive pulmonary disease	0.000755	0.00267	CcSEcCtD
Alprostadil—Syncope—Tiotropium—chronic obstructive pulmonary disease	0.000751	0.00266	CcSEcCtD
Alprostadil—PTGIR—Thromboxane A2 receptor signaling—NOS3—chronic obstructive pulmonary disease	0.000751	0.00566	CbGpPWpGaD
Alprostadil—Visual impairment—Arformoterol—chronic obstructive pulmonary disease	0.000748	0.00265	CcSEcCtD
Alprostadil—Visual impairment—Formoterol—chronic obstructive pulmonary disease	0.000748	0.00265	CcSEcCtD
Alprostadil—Urethral disorder—Montelukast—chronic obstructive pulmonary disease	0.000746	0.00264	CcSEcCtD
Alprostadil—Diarrhoea—Roflumilast—chronic obstructive pulmonary disease	0.000744	0.00263	CcSEcCtD
Alprostadil—Haemoglobin—Salbutamol—chronic obstructive pulmonary disease	0.000737	0.00261	CcSEcCtD
Alprostadil—Loss of consciousness—Tiotropium—chronic obstructive pulmonary disease	0.000736	0.0026	CcSEcCtD
Alprostadil—Rhinitis—Salbutamol—chronic obstructive pulmonary disease	0.000735	0.0026	CcSEcCtD
Alprostadil—Haemorrhage—Salbutamol—chronic obstructive pulmonary disease	0.000733	0.00259	CcSEcCtD
Alprostadil—Cough—Tiotropium—chronic obstructive pulmonary disease	0.000731	0.00259	CcSEcCtD
Alprostadil—PTGIR—G alpha (s) signalling events—ADRB2—chronic obstructive pulmonary disease	0.00073	0.00551	CbGpPWpGaD
Alprostadil—Hypoaesthesia—Salbutamol—chronic obstructive pulmonary disease	0.00073	0.00258	CcSEcCtD
Alprostadil—Pharyngitis—Salbutamol—chronic obstructive pulmonary disease	0.000728	0.00257	CcSEcCtD
Alprostadil—Hypertension—Tiotropium—chronic obstructive pulmonary disease	0.000723	0.00256	CcSEcCtD
Alprostadil—Infection—Aminophylline—chronic obstructive pulmonary disease	0.00072	0.00255	CcSEcCtD
Alprostadil—Dizziness—Roflumilast—chronic obstructive pulmonary disease	0.000719	0.00254	CcSEcCtD
Alprostadil—Urethral disorder—Salbutamol—chronic obstructive pulmonary disease	0.000719	0.00254	CcSEcCtD
Alprostadil—PTGIR—Platelet homeostasis—NOS2—chronic obstructive pulmonary disease	0.000716	0.0054	CbGpPWpGaD
Alprostadil—ABCC5—NRF2 pathway—TGFB2—chronic obstructive pulmonary disease	0.000716	0.0054	CbGpPWpGaD
Alprostadil—ABCC4—Platelet activation, signaling and aggregation—RAPGEF3—chronic obstructive pulmonary disease	0.000715	0.00539	CbGpPWpGaD
Alprostadil—Shock—Aminophylline—chronic obstructive pulmonary disease	0.000713	0.00252	CcSEcCtD
Alprostadil—PTGIR—Hemostasis—SERPINE2—chronic obstructive pulmonary disease	0.000708	0.00534	CbGpPWpGaD
Alprostadil—Tachycardia—Aminophylline—chronic obstructive pulmonary disease	0.000707	0.0025	CcSEcCtD
Alprostadil—ABCC5—NRF2 pathway—SLC6A4—chronic obstructive pulmonary disease	0.000702	0.00529	CbGpPWpGaD
Alprostadil—Diabetes mellitus—Prednisolone—chronic obstructive pulmonary disease	0.000699	0.00247	CcSEcCtD
Alprostadil—Dry mouth—Tiotropium—chronic obstructive pulmonary disease	0.000697	0.00247	CcSEcCtD
Alprostadil—Rash—Roflumilast—chronic obstructive pulmonary disease	0.000685	0.00242	CcSEcCtD
Alprostadil—Dermatitis—Roflumilast—chronic obstructive pulmonary disease	0.000685	0.00242	CcSEcCtD
Alprostadil—Oedema—Tiotropium—chronic obstructive pulmonary disease	0.000684	0.00242	CcSEcCtD
Alprostadil—Headache—Roflumilast—chronic obstructive pulmonary disease	0.000681	0.00241	CcSEcCtD
Alprostadil—Flushing—Salbutamol—chronic obstructive pulmonary disease	0.000681	0.00241	CcSEcCtD
Alprostadil—Infection—Tiotropium—chronic obstructive pulmonary disease	0.000679	0.0024	CcSEcCtD
Alprostadil—Hypotension—Aminophylline—chronic obstructive pulmonary disease	0.000677	0.0024	CcSEcCtD
Alprostadil—Shock—Tiotropium—chronic obstructive pulmonary disease	0.000673	0.00238	CcSEcCtD
Alprostadil—Cardiac failure congestive—Prednisolone—chronic obstructive pulmonary disease	0.00067	0.00237	CcSEcCtD
Alprostadil—Tachycardia—Tiotropium—chronic obstructive pulmonary disease	0.000667	0.00236	CcSEcCtD
Alprostadil—Skin disorder—Tiotropium—chronic obstructive pulmonary disease	0.000664	0.00235	CcSEcCtD
Alprostadil—Injury—Prednisolone—chronic obstructive pulmonary disease	0.000661	0.00234	CcSEcCtD
Alprostadil—Nervousness—Formoterol—chronic obstructive pulmonary disease	0.000657	0.00232	CcSEcCtD
Alprostadil—Nervousness—Arformoterol—chronic obstructive pulmonary disease	0.000657	0.00232	CcSEcCtD
Alprostadil—Back pain—Formoterol—chronic obstructive pulmonary disease	0.000654	0.00231	CcSEcCtD
Alprostadil—Back pain—Arformoterol—chronic obstructive pulmonary disease	0.000654	0.00231	CcSEcCtD
Alprostadil—Muscle spasms—Formoterol—chronic obstructive pulmonary disease	0.00065	0.0023	CcSEcCtD
Alprostadil—Muscle spasms—Arformoterol—chronic obstructive pulmonary disease	0.00065	0.0023	CcSEcCtD
Alprostadil—PTGIR—GPCRs, Class A Rhodopsin-like—CXCR2—chronic obstructive pulmonary disease	0.000648	0.00488	CbGpPWpGaD
Alprostadil—PTGER1—GPCRs, Class A Rhodopsin-like—CXCR2—chronic obstructive pulmonary disease	0.000648	0.00488	CbGpPWpGaD
Alprostadil—Nausea—Roflumilast—chronic obstructive pulmonary disease	0.000646	0.00228	CcSEcCtD
Alprostadil—Hypercholesterolaemia—Prednisone—chronic obstructive pulmonary disease	0.000643	0.00228	CcSEcCtD
Alprostadil—Dyspepsia—Aminophylline—chronic obstructive pulmonary disease	0.000638	0.00226	CcSEcCtD
Alprostadil—Muscle spasms—Montelukast—chronic obstructive pulmonary disease	0.000637	0.00225	CcSEcCtD
Alprostadil—PTGER2—GPCR ligand binding—CXCR2—chronic obstructive pulmonary disease	0.000626	0.00472	CbGpPWpGaD
Alprostadil—Nervousness—Salbutamol—chronic obstructive pulmonary disease	0.00062	0.00219	CcSEcCtD
Alprostadil—PTGIR—Hemostasis—RAPGEF3—chronic obstructive pulmonary disease	0.000619	0.00466	CbGpPWpGaD
Alprostadil—Back pain—Salbutamol—chronic obstructive pulmonary disease	0.000617	0.00218	CcSEcCtD
Alprostadil—Muscle spasms—Salbutamol—chronic obstructive pulmonary disease	0.000614	0.00217	CcSEcCtD
Alprostadil—Dyspepsia—Tiotropium—chronic obstructive pulmonary disease	0.000602	0.00213	CcSEcCtD
Alprostadil—PTGER2—GPCRs, Class A Rhodopsin-like—ADRB2—chronic obstructive pulmonary disease	0.000601	0.00454	CbGpPWpGaD
Alprostadil—ABCC4—Transmembrane transport of small molecules—ATP2C2—chronic obstructive pulmonary disease	0.000591	0.00446	CbGpPWpGaD
Alprostadil—Cough—Formoterol—chronic obstructive pulmonary disease	0.00059	0.00209	CcSEcCtD
Alprostadil—Cough—Arformoterol—chronic obstructive pulmonary disease	0.00059	0.00209	CcSEcCtD
Alprostadil—Hypertension—Formoterol—chronic obstructive pulmonary disease	0.000584	0.00206	CcSEcCtD
Alprostadil—Hypertension—Arformoterol—chronic obstructive pulmonary disease	0.000584	0.00206	CcSEcCtD
Alprostadil—Cardiac arrest—Prednisolone—chronic obstructive pulmonary disease	0.000578	0.00204	CcSEcCtD
Alprostadil—Cough—Montelukast—chronic obstructive pulmonary disease	0.000578	0.00204	CcSEcCtD
Alprostadil—PTGIR—Platelet homeostasis—NOS3—chronic obstructive pulmonary disease	0.000576	0.00434	CbGpPWpGaD
Alprostadil—Convulsion—Montelukast—chronic obstructive pulmonary disease	0.000574	0.00203	CcSEcCtD
Alprostadil—Abdominal pain—Aminophylline—chronic obstructive pulmonary disease	0.000573	0.00203	CcSEcCtD
Alprostadil—Body temperature increased—Aminophylline—chronic obstructive pulmonary disease	0.000573	0.00203	CcSEcCtD
Alprostadil—Syncope—Salbutamol—chronic obstructive pulmonary disease	0.000572	0.00202	CcSEcCtD
Alprostadil—ABCC4—NRF2 pathway—SERPINA1—chronic obstructive pulmonary disease	0.000572	0.00432	CbGpPWpGaD
Alprostadil—Discomfort—Arformoterol—chronic obstructive pulmonary disease	0.000569	0.00201	CcSEcCtD
Alprostadil—Discomfort—Formoterol—chronic obstructive pulmonary disease	0.000569	0.00201	CcSEcCtD
Alprostadil—Dry mouth—Arformoterol—chronic obstructive pulmonary disease	0.000563	0.00199	CcSEcCtD
Alprostadil—Dry mouth—Formoterol—chronic obstructive pulmonary disease	0.000563	0.00199	CcSEcCtD
Alprostadil—Loss of consciousness—Salbutamol—chronic obstructive pulmonary disease	0.000561	0.00198	CcSEcCtD
Alprostadil—Cough—Salbutamol—chronic obstructive pulmonary disease	0.000557	0.00197	CcSEcCtD
Alprostadil—PTGIR—Class A/1 (Rhodopsin-like receptors)—CXCR2—chronic obstructive pulmonary disease	0.000555	0.00418	CbGpPWpGaD
Alprostadil—PTGER1—Class A/1 (Rhodopsin-like receptors)—CXCR2—chronic obstructive pulmonary disease	0.000555	0.00418	CbGpPWpGaD
Alprostadil—Oedema—Formoterol—chronic obstructive pulmonary disease	0.000552	0.00195	CcSEcCtD
Alprostadil—Oedema—Arformoterol—chronic obstructive pulmonary disease	0.000552	0.00195	CcSEcCtD
Alprostadil—Hypertension—Salbutamol—chronic obstructive pulmonary disease	0.000551	0.00195	CcSEcCtD
Alprostadil—Ecchymosis—Prednisone—chronic obstructive pulmonary disease	0.00055	0.00195	CcSEcCtD
Alprostadil—Infection—Formoterol—chronic obstructive pulmonary disease	0.000548	0.00194	CcSEcCtD
Alprostadil—Infection—Arformoterol—chronic obstructive pulmonary disease	0.000548	0.00194	CcSEcCtD
Alprostadil—Abdominal pain—Tiotropium—chronic obstructive pulmonary disease	0.00054	0.00191	CcSEcCtD
Alprostadil—Oedema—Montelukast—chronic obstructive pulmonary disease	0.00054	0.00191	CcSEcCtD
Alprostadil—Tachycardia—Arformoterol—chronic obstructive pulmonary disease	0.000538	0.0019	CcSEcCtD
Alprostadil—Tachycardia—Formoterol—chronic obstructive pulmonary disease	0.000538	0.0019	CcSEcCtD
Alprostadil—Discomfort—Salbutamol—chronic obstructive pulmonary disease	0.000537	0.0019	CcSEcCtD
Alprostadil—Infection—Montelukast—chronic obstructive pulmonary disease	0.000537	0.0019	CcSEcCtD
Alprostadil—ABCC5—Fluoropyrimidine Activity—TP53—chronic obstructive pulmonary disease	0.000537	0.00405	CbGpPWpGaD
Alprostadil—Skin disorder—Arformoterol—chronic obstructive pulmonary disease	0.000536	0.0019	CcSEcCtD
Alprostadil—Skin disorder—Formoterol—chronic obstructive pulmonary disease	0.000536	0.0019	CcSEcCtD
Alprostadil—Dry mouth—Salbutamol—chronic obstructive pulmonary disease	0.000531	0.00188	CcSEcCtD
Alprostadil—ABCC5—NRF2 pathway—GSTP1—chronic obstructive pulmonary disease	0.00053	0.00399	CbGpPWpGaD
Alprostadil—Thrombocytopenia—Montelukast—chronic obstructive pulmonary disease	0.000529	0.00187	CcSEcCtD
Alprostadil—Sepsis—Prednisone—chronic obstructive pulmonary disease	0.000528	0.00187	CcSEcCtD
Alprostadil—ABCC4—Transmembrane transport of small molecules—TRPV4—chronic obstructive pulmonary disease	0.000527	0.00397	CbGpPWpGaD
Alprostadil—Skin disorder—Montelukast—chronic obstructive pulmonary disease	0.000525	0.00186	CcSEcCtD
Alprostadil—ABCC4—NRF2 pathway—GCLC—chronic obstructive pulmonary disease	0.000523	0.00395	CbGpPWpGaD
Alprostadil—ABCC5—NRF2 pathway—HMOX1—chronic obstructive pulmonary disease	0.000522	0.00394	CbGpPWpGaD
Alprostadil—Oedema—Salbutamol—chronic obstructive pulmonary disease	0.000521	0.00184	CcSEcCtD
Alprostadil—Infection—Salbutamol—chronic obstructive pulmonary disease	0.000518	0.00183	CcSEcCtD
Alprostadil—Hypotension—Formoterol—chronic obstructive pulmonary disease	0.000516	0.00182	CcSEcCtD
Alprostadil—Hypotension—Arformoterol—chronic obstructive pulmonary disease	0.000516	0.00182	CcSEcCtD
Alprostadil—PTGER2—Class A/1 (Rhodopsin-like receptors)—ADRB2—chronic obstructive pulmonary disease	0.000515	0.00389	CbGpPWpGaD
Alprostadil—Pruritus—Aminophylline—chronic obstructive pulmonary disease	0.000513	0.00181	CcSEcCtD
Alprostadil—Shock—Salbutamol—chronic obstructive pulmonary disease	0.000513	0.00181	CcSEcCtD
Alprostadil—PTGER2—Signaling Pathways—FAM13A—chronic obstructive pulmonary disease	0.000512	0.00386	CbGpPWpGaD
Alprostadil—Sweating increased—Prednisolone—chronic obstructive pulmonary disease	0.000512	0.00181	CcSEcCtD
Alprostadil—Tachycardia—Salbutamol—chronic obstructive pulmonary disease	0.000508	0.0018	CcSEcCtD
Alprostadil—Diabetes mellitus—Prednisone—chronic obstructive pulmonary disease	0.000508	0.0018	CcSEcCtD
Alprostadil—Skin disorder—Salbutamol—chronic obstructive pulmonary disease	0.000506	0.00179	CcSEcCtD
Alprostadil—Hyperhidrosis—Salbutamol—chronic obstructive pulmonary disease	0.000504	0.00178	CcSEcCtD
Alprostadil—ABCC4—NRF2 pathway—TGFB2—chronic obstructive pulmonary disease	0.000496	0.00374	CbGpPWpGaD
Alprostadil—Diarrhoea—Aminophylline—chronic obstructive pulmonary disease	0.000496	0.00175	CcSEcCtD
Alprostadil—Cardiac failure congestive—Prednisone—chronic obstructive pulmonary disease	0.000487	0.00172	CcSEcCtD
Alprostadil—PTGIR—Thromboxane A2 receptor signaling—EGFR—chronic obstructive pulmonary disease	0.000487	0.00367	CbGpPWpGaD
Alprostadil—Hypotension—Salbutamol—chronic obstructive pulmonary disease	0.000487	0.00172	CcSEcCtD
Alprostadil—ABCC4—NRF2 pathway—SLC6A4—chronic obstructive pulmonary disease	0.000487	0.00367	CbGpPWpGaD
Alprostadil—ABCC5—NRF2 pathway—GSTM1—chronic obstructive pulmonary disease	0.000487	0.00367	CbGpPWpGaD
Alprostadil—Dyspepsia—Arformoterol—chronic obstructive pulmonary disease	0.000486	0.00172	CcSEcCtD
Alprostadil—Dyspepsia—Formoterol—chronic obstructive pulmonary disease	0.000486	0.00172	CcSEcCtD
Alprostadil—Pruritus—Tiotropium—chronic obstructive pulmonary disease	0.000484	0.00171	CcSEcCtD
Alprostadil—Injury—Prednisone—chronic obstructive pulmonary disease	0.000481	0.0017	CcSEcCtD
Alprostadil—Dizziness—Aminophylline—chronic obstructive pulmonary disease	0.000479	0.0017	CcSEcCtD
Alprostadil—Dyspepsia—Montelukast—chronic obstructive pulmonary disease	0.000476	0.00168	CcSEcCtD
Alprostadil—Pain—Formoterol—chronic obstructive pulmonary disease	0.000472	0.00167	CcSEcCtD
Alprostadil—Pain—Arformoterol—chronic obstructive pulmonary disease	0.000472	0.00167	CcSEcCtD
Alprostadil—PTGER2—GPCRs, Class A Rhodopsin-like—HTR2A—chronic obstructive pulmonary disease	0.00047	0.00355	CbGpPWpGaD
Alprostadil—PTGER1—G alpha (q) signalling events—EDN1—chronic obstructive pulmonary disease	0.00047	0.00354	CbGpPWpGaD
Alprostadil—Pain—Montelukast—chronic obstructive pulmonary disease	0.000462	0.00163	CcSEcCtD
Alprostadil—Acute coronary syndrome—Prednisolone—chronic obstructive pulmonary disease	0.000462	0.00163	CcSEcCtD
Alprostadil—PTGER2—Class A/1 (Rhodopsin-like receptors)—EDN1—chronic obstructive pulmonary disease	0.000461	0.00347	CbGpPWpGaD
Alprostadil—Myocardial infarction—Prednisolone—chronic obstructive pulmonary disease	0.000459	0.00162	CcSEcCtD
Alprostadil—Dyspepsia—Salbutamol—chronic obstructive pulmonary disease	0.000459	0.00162	CcSEcCtD
Alprostadil—Rash—Aminophylline—chronic obstructive pulmonary disease	0.000457	0.00162	CcSEcCtD
Alprostadil—Dermatitis—Aminophylline—chronic obstructive pulmonary disease	0.000457	0.00162	CcSEcCtD
Alprostadil—Feeling abnormal—Formoterol—chronic obstructive pulmonary disease	0.000455	0.00161	CcSEcCtD
Alprostadil—Feeling abnormal—Arformoterol—chronic obstructive pulmonary disease	0.000455	0.00161	CcSEcCtD
Alprostadil—Headache—Aminophylline—chronic obstructive pulmonary disease	0.000454	0.00161	CcSEcCtD
Alprostadil—Dizziness—Tiotropium—chronic obstructive pulmonary disease	0.000452	0.0016	CcSEcCtD
Alprostadil—Lethargy—Prednisone—chronic obstructive pulmonary disease	0.000451	0.00159	CcSEcCtD
Alprostadil—Pain—Salbutamol—chronic obstructive pulmonary disease	0.000445	0.00158	CcSEcCtD
Alprostadil—PTGER2—GPCR downstream signaling—PDE4A—chronic obstructive pulmonary disease	0.000439	0.00331	CbGpPWpGaD
Alprostadil—Body temperature increased—Formoterol—chronic obstructive pulmonary disease	0.000436	0.00154	CcSEcCtD
Alprostadil—Abdominal pain—Arformoterol—chronic obstructive pulmonary disease	0.000436	0.00154	CcSEcCtD
Alprostadil—Body temperature increased—Arformoterol—chronic obstructive pulmonary disease	0.000436	0.00154	CcSEcCtD
Alprostadil—Abdominal pain—Formoterol—chronic obstructive pulmonary disease	0.000436	0.00154	CcSEcCtD
Alprostadil—Rash—Tiotropium—chronic obstructive pulmonary disease	0.000431	0.00152	CcSEcCtD
Alprostadil—Dermatitis—Tiotropium—chronic obstructive pulmonary disease	0.000431	0.00152	CcSEcCtD
Alprostadil—Nausea—Aminophylline—chronic obstructive pulmonary disease	0.000431	0.00152	CcSEcCtD
Alprostadil—Feeling abnormal—Salbutamol—chronic obstructive pulmonary disease	0.000429	0.00152	CcSEcCtD
Alprostadil—Headache—Tiotropium—chronic obstructive pulmonary disease	0.000428	0.00151	CcSEcCtD
Alprostadil—Bradycardia—Prednisolone—chronic obstructive pulmonary disease	0.000428	0.00151	CcSEcCtD
Alprostadil—Body temperature increased—Montelukast—chronic obstructive pulmonary disease	0.000427	0.00151	CcSEcCtD
Alprostadil—Abdominal pain—Montelukast—chronic obstructive pulmonary disease	0.000427	0.00151	CcSEcCtD
Alprostadil—Haemoglobin—Prednisolone—chronic obstructive pulmonary disease	0.000423	0.00149	CcSEcCtD
Alprostadil—PTGIR—GPCR ligand binding—CXCR2—chronic obstructive pulmonary disease	0.000423	0.00319	CbGpPWpGaD
Alprostadil—PTGER1—GPCR ligand binding—CXCR2—chronic obstructive pulmonary disease	0.000423	0.00319	CbGpPWpGaD
Alprostadil—ABCC4—Hemostasis—SERPINE2—chronic obstructive pulmonary disease	0.000422	0.00318	CbGpPWpGaD
Alprostadil—Haemorrhage—Prednisolone—chronic obstructive pulmonary disease	0.000421	0.00149	CcSEcCtD
Alprostadil—PTGER1—Gastrin-CREB signalling pathway via PKC and MAPK—EDN1—chronic obstructive pulmonary disease	0.00042	0.00317	CbGpPWpGaD
Alprostadil—Cardiac arrest—Prednisone—chronic obstructive pulmonary disease	0.00042	0.00149	CcSEcCtD
Alprostadil—Body temperature increased—Salbutamol—chronic obstructive pulmonary disease	0.000412	0.00146	CcSEcCtD
Alprostadil—Abdominal pain—Salbutamol—chronic obstructive pulmonary disease	0.000412	0.00146	CcSEcCtD
Alprostadil—PTGER1—G alpha (q) signalling events—HTR2A—chronic obstructive pulmonary disease	0.000411	0.0031	CbGpPWpGaD
Alprostadil—ABCC4—Platelet activation, signaling and aggregation—SERPINA1—chronic obstructive pulmonary disease	0.000411	0.0031	CbGpPWpGaD
Alprostadil—PTGER1—GPCRs, Class A Rhodopsin-like—ADRB2—chronic obstructive pulmonary disease	0.000406	0.00306	CbGpPWpGaD
Alprostadil—PTGIR—GPCRs, Class A Rhodopsin-like—ADRB2—chronic obstructive pulmonary disease	0.000406	0.00306	CbGpPWpGaD
Alprostadil—Nausea—Tiotropium—chronic obstructive pulmonary disease	0.000406	0.00144	CcSEcCtD
Alprostadil—Visual impairment—Prednisolone—chronic obstructive pulmonary disease	0.000405	0.00143	CcSEcCtD
Alprostadil—PTGER2—Class A/1 (Rhodopsin-like receptors)—HTR2A—chronic obstructive pulmonary disease	0.000403	0.00304	CbGpPWpGaD
Alprostadil—Hypokalaemia—Prednisone—chronic obstructive pulmonary disease	0.000402	0.00142	CcSEcCtD
Alprostadil—PTGER2—Signaling by GPCR—PDE4A—chronic obstructive pulmonary disease	0.000398	0.003	CbGpPWpGaD
Alprostadil—Asthenia—Arformoterol—chronic obstructive pulmonary disease	0.000396	0.0014	CcSEcCtD
Alprostadil—Asthenia—Formoterol—chronic obstructive pulmonary disease	0.000396	0.0014	CcSEcCtD
Alprostadil—PTGER2—GPCR ligand binding—ADRB2—chronic obstructive pulmonary disease	0.000392	0.00296	CbGpPWpGaD
Alprostadil—Pruritus—Formoterol—chronic obstructive pulmonary disease	0.00039	0.00138	CcSEcCtD
Alprostadil—Pruritus—Arformoterol—chronic obstructive pulmonary disease	0.00039	0.00138	CcSEcCtD
Alprostadil—Asthenia—Montelukast—chronic obstructive pulmonary disease	0.000388	0.00137	CcSEcCtD
Alprostadil—Pruritus—Montelukast—chronic obstructive pulmonary disease	0.000382	0.00135	CcSEcCtD
Alprostadil—Diarrhoea—Arformoterol—chronic obstructive pulmonary disease	0.000377	0.00134	CcSEcCtD
Alprostadil—Diarrhoea—Formoterol—chronic obstructive pulmonary disease	0.000377	0.00134	CcSEcCtD
Alprostadil—SLCO2A1—SLC-mediated transmembrane transport—ALB—chronic obstructive pulmonary disease	0.000376	0.00284	CbGpPWpGaD
Alprostadil—Asthenia—Salbutamol—chronic obstructive pulmonary disease	0.000374	0.00132	CcSEcCtD
Alprostadil—ABCC4—Fluoropyrimidine Activity—TP53—chronic obstructive pulmonary disease	0.000372	0.0028	CbGpPWpGaD
Alprostadil—Sweating increased—Prednisone—chronic obstructive pulmonary disease	0.000372	0.00132	CcSEcCtD
Alprostadil—Diarrhoea—Montelukast—chronic obstructive pulmonary disease	0.00037	0.00131	CcSEcCtD
Alprostadil—ABCC4—Hemostasis—RAPGEF3—chronic obstructive pulmonary disease	0.000369	0.00278	CbGpPWpGaD
Alprostadil—Pruritus—Salbutamol—chronic obstructive pulmonary disease	0.000369	0.0013	CcSEcCtD
Alprostadil—PTGER1—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—chronic obstructive pulmonary disease	0.000367	0.00277	CbGpPWpGaD
Alprostadil—ABCC4—NRF2 pathway—GSTP1—chronic obstructive pulmonary disease	0.000367	0.00277	CbGpPWpGaD
Alprostadil—Erythema—Prednisolone—chronic obstructive pulmonary disease	0.000366	0.00129	CcSEcCtD
Alprostadil—Dizziness—Arformoterol—chronic obstructive pulmonary disease	0.000365	0.00129	CcSEcCtD
Alprostadil—Dizziness—Formoterol—chronic obstructive pulmonary disease	0.000365	0.00129	CcSEcCtD
Alprostadil—ABCC4—NRF2 pathway—HMOX1—chronic obstructive pulmonary disease	0.000362	0.00273	CbGpPWpGaD
Alprostadil—Dizziness—Montelukast—chronic obstructive pulmonary disease	0.000357	0.00126	CcSEcCtD
Alprostadil—SLCO3A1—SLC-mediated transmembrane transport—ALB—chronic obstructive pulmonary disease	0.000357	0.00269	CbGpPWpGaD
Alprostadil—Diarrhoea—Salbutamol—chronic obstructive pulmonary disease	0.000356	0.00126	CcSEcCtD
Alprostadil—ABCC4—Platelet activation, signaling and aggregation—TGFB2—chronic obstructive pulmonary disease	0.000356	0.00269	CbGpPWpGaD
Alprostadil—PTGIR—Hemostasis—SERPINA1—chronic obstructive pulmonary disease	0.000355	0.00268	CbGpPWpGaD
Alprostadil—PTGER2—GPCR downstream signaling—CXCR2—chronic obstructive pulmonary disease	0.000354	0.00267	CbGpPWpGaD
Alprostadil—ABCC4—Platelet degranulation—SERPINE1—chronic obstructive pulmonary disease	0.000352	0.00266	CbGpPWpGaD
Alprostadil—ABCC4—Platelet degranulation—ALB—chronic obstructive pulmonary disease	0.000352	0.00265	CbGpPWpGaD
Alprostadil—PTGER2—GPCR ligand binding—EDN1—chronic obstructive pulmonary disease	0.000351	0.00264	CbGpPWpGaD
Alprostadil—PTGIR—Class A/1 (Rhodopsin-like receptors)—ADRB2—chronic obstructive pulmonary disease	0.000348	0.00262	CbGpPWpGaD
Alprostadil—PTGER1—Class A/1 (Rhodopsin-like receptors)—ADRB2—chronic obstructive pulmonary disease	0.000348	0.00262	CbGpPWpGaD
Alprostadil—Rash—Arformoterol—chronic obstructive pulmonary disease	0.000348	0.00123	CcSEcCtD
Alprostadil—Rash—Formoterol—chronic obstructive pulmonary disease	0.000348	0.00123	CcSEcCtD
Alprostadil—Dermatitis—Formoterol—chronic obstructive pulmonary disease	0.000348	0.00123	CcSEcCtD
Alprostadil—Dermatitis—Arformoterol—chronic obstructive pulmonary disease	0.000348	0.00123	CcSEcCtD
Alprostadil—PTGER1—Signaling Pathways—FAM13A—chronic obstructive pulmonary disease	0.000346	0.00261	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—FAM13A—chronic obstructive pulmonary disease	0.000346	0.00261	CbGpPWpGaD
Alprostadil—Headache—Arformoterol—chronic obstructive pulmonary disease	0.000346	0.00122	CcSEcCtD
Alprostadil—Headache—Formoterol—chronic obstructive pulmonary disease	0.000346	0.00122	CcSEcCtD
Alprostadil—Dizziness—Salbutamol—chronic obstructive pulmonary disease	0.000344	0.00122	CcSEcCtD
Alprostadil—Hyperglycaemia—Prednisone—chronic obstructive pulmonary disease	0.000344	0.00122	CcSEcCtD
Alprostadil—Rash—Montelukast—chronic obstructive pulmonary disease	0.000341	0.00121	CcSEcCtD
Alprostadil—Dermatitis—Montelukast—chronic obstructive pulmonary disease	0.00034	0.0012	CcSEcCtD
Alprostadil—Headache—Montelukast—chronic obstructive pulmonary disease	0.000339	0.0012	CcSEcCtD
Alprostadil—ABCC4—NRF2 pathway—GSTM1—chronic obstructive pulmonary disease	0.000337	0.00254	CbGpPWpGaD
Alprostadil—ABCC4—Response to elevated platelet cytosolic Ca2+—SERPINE1—chronic obstructive pulmonary disease	0.000336	0.00253	CbGpPWpGaD
Alprostadil—Acute coronary syndrome—Prednisone—chronic obstructive pulmonary disease	0.000336	0.00119	CcSEcCtD
Alprostadil—ABCC4—Response to elevated platelet cytosolic Ca2+—ALB—chronic obstructive pulmonary disease	0.000335	0.00253	CbGpPWpGaD
Alprostadil—Myocardial infarction—Prednisone—chronic obstructive pulmonary disease	0.000334	0.00118	CcSEcCtD
Alprostadil—Rash—Salbutamol—chronic obstructive pulmonary disease	0.000328	0.00116	CcSEcCtD
Alprostadil—Syncope—Prednisolone—chronic obstructive pulmonary disease	0.000328	0.00116	CcSEcCtD
Alprostadil—Dermatitis—Salbutamol—chronic obstructive pulmonary disease	0.000328	0.00116	CcSEcCtD
Alprostadil—Nausea—Arformoterol—chronic obstructive pulmonary disease	0.000328	0.00116	CcSEcCtD
Alprostadil—Nausea—Formoterol—chronic obstructive pulmonary disease	0.000328	0.00116	CcSEcCtD
Alprostadil—Headache—Salbutamol—chronic obstructive pulmonary disease	0.000326	0.00115	CcSEcCtD
Alprostadil—ABCC5—Metabolism—APIP—chronic obstructive pulmonary disease	0.000326	0.00245	CbGpPWpGaD
Alprostadil—Loss of consciousness—Prednisolone—chronic obstructive pulmonary disease	0.000322	0.00114	CcSEcCtD
Alprostadil—PTGER2—Signaling by GPCR—CXCR2—chronic obstructive pulmonary disease	0.000321	0.00242	CbGpPWpGaD
Alprostadil—Nausea—Montelukast—chronic obstructive pulmonary disease	0.000321	0.00114	CcSEcCtD
Alprostadil—SLCO2A1—Transmembrane transport of small molecules—HMOX1—chronic obstructive pulmonary disease	0.000318	0.0024	CbGpPWpGaD
Alprostadil—PTGIR—GPCRs, Class A Rhodopsin-like—HTR2A—chronic obstructive pulmonary disease	0.000318	0.0024	CbGpPWpGaD
Alprostadil—PTGER1—GPCRs, Class A Rhodopsin-like—HTR2A—chronic obstructive pulmonary disease	0.000318	0.0024	CbGpPWpGaD
Alprostadil—Convulsion—Prednisolone—chronic obstructive pulmonary disease	0.000317	0.00112	CcSEcCtD
Alprostadil—Hypertension—Prednisolone—chronic obstructive pulmonary disease	0.000316	0.00112	CcSEcCtD
Alprostadil—Bradycardia—Prednisone—chronic obstructive pulmonary disease	0.000311	0.0011	CcSEcCtD
Alprostadil—PTGER1—Class A/1 (Rhodopsin-like receptors)—EDN1—chronic obstructive pulmonary disease	0.000311	0.00235	CbGpPWpGaD
Alprostadil—PTGIR—Class A/1 (Rhodopsin-like receptors)—EDN1—chronic obstructive pulmonary disease	0.000311	0.00235	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—RAPGEF3—chronic obstructive pulmonary disease	0.00031	0.00234	CbGpPWpGaD
Alprostadil—Nausea—Salbutamol—chronic obstructive pulmonary disease	0.000309	0.00109	CcSEcCtD
Alprostadil—PTGIR—Hemostasis—TGFB2—chronic obstructive pulmonary disease	0.000308	0.00232	CbGpPWpGaD
Alprostadil—Discomfort—Prednisolone—chronic obstructive pulmonary disease	0.000308	0.00109	CcSEcCtD
Alprostadil—Haemoglobin—Prednisone—chronic obstructive pulmonary disease	0.000307	0.00109	CcSEcCtD
Alprostadil—PTGER2—GPCR ligand binding—HTR2A—chronic obstructive pulmonary disease	0.000307	0.00231	CbGpPWpGaD
Alprostadil—Haemorrhage—Prednisone—chronic obstructive pulmonary disease	0.000306	0.00108	CcSEcCtD
Alprostadil—SLCO3A1—Transmembrane transport of small molecules—HMOX1—chronic obstructive pulmonary disease	0.000302	0.00228	CbGpPWpGaD
Alprostadil—Oedema—Prednisolone—chronic obstructive pulmonary disease	0.000299	0.00106	CcSEcCtD
Alprostadil—PTGER1—GPCR downstream signaling—PDE4A—chronic obstructive pulmonary disease	0.000296	0.00223	CbGpPWpGaD
Alprostadil—PTGIR—GPCR downstream signaling—PDE4A—chronic obstructive pulmonary disease	0.000296	0.00223	CbGpPWpGaD
Alprostadil—Shock—Prednisolone—chronic obstructive pulmonary disease	0.000294	0.00104	CcSEcCtD
Alprostadil—Tachycardia—Prednisolone—chronic obstructive pulmonary disease	0.000292	0.00103	CcSEcCtD
Alprostadil—Hyperhidrosis—Prednisolone—chronic obstructive pulmonary disease	0.000289	0.00102	CcSEcCtD
Alprostadil—Flushing—Prednisone—chronic obstructive pulmonary disease	0.000284	0.001	CcSEcCtD
Alprostadil—PTGIR—Hemostasis—HDAC2—chronic obstructive pulmonary disease	0.000276	0.00208	CbGpPWpGaD
Alprostadil—PTGIR—Class A/1 (Rhodopsin-like receptors)—HTR2A—chronic obstructive pulmonary disease	0.000272	0.00205	CbGpPWpGaD
Alprostadil—PTGER1—Class A/1 (Rhodopsin-like receptors)—HTR2A—chronic obstructive pulmonary disease	0.000272	0.00205	CbGpPWpGaD
Alprostadil—PTGER1—Signaling by GPCR—PDE4A—chronic obstructive pulmonary disease	0.000269	0.00203	CbGpPWpGaD
Alprostadil—PTGIR—Signaling by GPCR—PDE4A—chronic obstructive pulmonary disease	0.000269	0.00203	CbGpPWpGaD
Alprostadil—Erythema—Prednisone—chronic obstructive pulmonary disease	0.000266	0.000941	CcSEcCtD
Alprostadil—PTGER1—GPCR ligand binding—ADRB2—chronic obstructive pulmonary disease	0.000265	0.002	CbGpPWpGaD
Alprostadil—PTGIR—GPCR ligand binding—ADRB2—chronic obstructive pulmonary disease	0.000265	0.002	CbGpPWpGaD
Alprostadil—Pain—Prednisolone—chronic obstructive pulmonary disease	0.000256	0.000904	CcSEcCtD
Alprostadil—PTGIR—Hemostasis—PLAUR—chronic obstructive pulmonary disease	0.000249	0.00188	CbGpPWpGaD
Alprostadil—PTGER2—Class A/1 (Rhodopsin-like receptors)—CXCL8—chronic obstructive pulmonary disease	0.000249	0.00188	CbGpPWpGaD
Alprostadil—Feeling abnormal—Prednisolone—chronic obstructive pulmonary disease	0.000246	0.000871	CcSEcCtD
Alprostadil—Anaemia—Prednisone—chronic obstructive pulmonary disease	0.000246	0.00087	CcSEcCtD
Alprostadil—ABCC4—Platelet degranulation—VEGFA—chronic obstructive pulmonary disease	0.000242	0.00183	CbGpPWpGaD
Alprostadil—PTGIR—GPCR downstream signaling—CXCR2—chronic obstructive pulmonary disease	0.000239	0.0018	CbGpPWpGaD
Alprostadil—PTGER1—GPCR downstream signaling—CXCR2—chronic obstructive pulmonary disease	0.000239	0.0018	CbGpPWpGaD
Alprostadil—Syncope—Prednisone—chronic obstructive pulmonary disease	0.000239	0.000844	CcSEcCtD
Alprostadil—PTGIR—GPCR ligand binding—EDN1—chronic obstructive pulmonary disease	0.000237	0.00179	CbGpPWpGaD
Alprostadil—PTGER1—GPCR ligand binding—EDN1—chronic obstructive pulmonary disease	0.000237	0.00179	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—PDE4A—chronic obstructive pulmonary disease	0.000235	0.00177	CbGpPWpGaD
Alprostadil—Loss of consciousness—Prednisone—chronic obstructive pulmonary disease	0.000234	0.000827	CcSEcCtD
Alprostadil—ABCC4—Response to elevated platelet cytosolic Ca2+—VEGFA—chronic obstructive pulmonary disease	0.000231	0.00174	CbGpPWpGaD
Alprostadil—Convulsion—Prednisone—chronic obstructive pulmonary disease	0.00023	0.000815	CcSEcCtD
Alprostadil—Hypertension—Prednisone—chronic obstructive pulmonary disease	0.00023	0.000812	CcSEcCtD
Alprostadil—Discomfort—Prednisone—chronic obstructive pulmonary disease	0.000224	0.000791	CcSEcCtD
Alprostadil—ABCC4—Platelet degranulation—TGFB1—chronic obstructive pulmonary disease	0.000222	0.00168	CbGpPWpGaD
Alprostadil—PTGER2—GPCR downstream signaling—ADRB2—chronic obstructive pulmonary disease	0.000222	0.00167	CbGpPWpGaD
Alprostadil—Oedema—Prednisone—chronic obstructive pulmonary disease	0.000217	0.000768	CcSEcCtD
Alprostadil—PTGIR—Signaling by GPCR—CXCR2—chronic obstructive pulmonary disease	0.000217	0.00164	CbGpPWpGaD
Alprostadil—PTGER1—Signaling by GPCR—CXCR2—chronic obstructive pulmonary disease	0.000217	0.00164	CbGpPWpGaD
Alprostadil—Infection—Prednisone—chronic obstructive pulmonary disease	0.000216	0.000763	CcSEcCtD
Alprostadil—ABCC5—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	0.000216	0.00163	CbGpPWpGaD
Alprostadil—Shock—Prednisone—chronic obstructive pulmonary disease	0.000214	0.000756	CcSEcCtD
Alprostadil—ABCC4—Response to elevated platelet cytosolic Ca2+—TGFB1—chronic obstructive pulmonary disease	0.000212	0.0016	CbGpPWpGaD
Alprostadil—Tachycardia—Prednisone—chronic obstructive pulmonary disease	0.000212	0.000749	CcSEcCtD
Alprostadil—ABCC4—Hemostasis—SERPINA1—chronic obstructive pulmonary disease	0.000212	0.0016	CbGpPWpGaD
Alprostadil—Skin disorder—Prednisone—chronic obstructive pulmonary disease	0.000211	0.000746	CcSEcCtD
Alprostadil—Hyperhidrosis—Prednisone—chronic obstructive pulmonary disease	0.00021	0.000742	CcSEcCtD
Alprostadil—ABCC5—Metabolism—GC—chronic obstructive pulmonary disease	0.00021	0.00158	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—RAPGEF3—chronic obstructive pulmonary disease	0.00021	0.00158	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—RAPGEF3—chronic obstructive pulmonary disease	0.00021	0.00158	CbGpPWpGaD
Alprostadil—PTGER1—GPCR ligand binding—HTR2A—chronic obstructive pulmonary disease	0.000207	0.00156	CbGpPWpGaD
Alprostadil—PTGIR—GPCR ligand binding—HTR2A—chronic obstructive pulmonary disease	0.000207	0.00156	CbGpPWpGaD
Alprostadil—SLCO2B1—SLC-mediated transmembrane transport—ALB—chronic obstructive pulmonary disease	0.000207	0.00156	CbGpPWpGaD
Alprostadil—PTGER2—Signaling by GPCR—ADRB2—chronic obstructive pulmonary disease	0.000201	0.00152	CbGpPWpGaD
Alprostadil—ABCC5—NRF2 pathway—TGFB1—chronic obstructive pulmonary disease	0.000198	0.0015	CbGpPWpGaD
Alprostadil—PTGER2—GPCR downstream signaling—EDN1—chronic obstructive pulmonary disease	0.000198	0.00149	CbGpPWpGaD
Alprostadil—Dizziness—Prednisolone—chronic obstructive pulmonary disease	0.000198	0.000699	CcSEcCtD
Alprostadil—ABCC5—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	0.000195	0.00147	CbGpPWpGaD
Alprostadil—SLCO2A1—Transmembrane transport of small molecules—ALB—chronic obstructive pulmonary disease	0.000191	0.00144	CbGpPWpGaD
Alprostadil—Dyspepsia—Prednisone—chronic obstructive pulmonary disease	0.000191	0.000676	CcSEcCtD
Alprostadil—PTGER2—Signaling Pathways—CXCR2—chronic obstructive pulmonary disease	0.00019	0.00143	CbGpPWpGaD
Alprostadil—PTGER2—GPCR ligand binding—CXCL8—chronic obstructive pulmonary disease	0.00019	0.00143	CbGpPWpGaD
Alprostadil—Rash—Prednisolone—chronic obstructive pulmonary disease	0.000188	0.000666	CcSEcCtD
Alprostadil—Dermatitis—Prednisolone—chronic obstructive pulmonary disease	0.000188	0.000666	CcSEcCtD
Alprostadil—Headache—Prednisolone—chronic obstructive pulmonary disease	0.000187	0.000662	CcSEcCtD
Alprostadil—ABCC4—Hemostasis—TGFB2—chronic obstructive pulmonary disease	0.000184	0.00138	CbGpPWpGaD
Alprostadil—SLCO3A1—Transmembrane transport of small molecules—ALB—chronic obstructive pulmonary disease	0.000181	0.00137	CbGpPWpGaD
Alprostadil—PTGER2—Signaling by GPCR—EDN1—chronic obstructive pulmonary disease	0.00018	0.00136	CbGpPWpGaD
Alprostadil—Feeling abnormal—Prednisone—chronic obstructive pulmonary disease	0.000179	0.000633	CcSEcCtD
Alprostadil—PTGIR—Hemostasis—MMP1—chronic obstructive pulmonary disease	0.000178	0.00134	CbGpPWpGaD
Alprostadil—Nausea—Prednisolone—chronic obstructive pulmonary disease	0.000177	0.000628	CcSEcCtD
Alprostadil—SLCO2B1—Transmembrane transport of small molecules—HMOX1—chronic obstructive pulmonary disease	0.000175	0.00132	CbGpPWpGaD
Alprostadil—PTGIR—Hemostasis—PLAU—chronic obstructive pulmonary disease	0.000175	0.00132	CbGpPWpGaD
Alprostadil—PTGER2—GPCR downstream signaling—HTR2A—chronic obstructive pulmonary disease	0.000173	0.00131	CbGpPWpGaD
Alprostadil—Body temperature increased—Prednisone—chronic obstructive pulmonary disease	0.000172	0.000607	CcSEcCtD
Alprostadil—Abdominal pain—Prednisone—chronic obstructive pulmonary disease	0.000172	0.000607	CcSEcCtD
Alprostadil—PTGIR—Class A/1 (Rhodopsin-like receptors)—CXCL8—chronic obstructive pulmonary disease	0.000168	0.00127	CbGpPWpGaD
Alprostadil—PTGER1—Class A/1 (Rhodopsin-like receptors)—CXCL8—chronic obstructive pulmonary disease	0.000168	0.00127	CbGpPWpGaD
Alprostadil—ABCC5—Transmembrane transport of small molecules—HMOX1—chronic obstructive pulmonary disease	0.000167	0.00126	CbGpPWpGaD
Alprostadil—PTGER1—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—chronic obstructive pulmonary disease	0.000166	0.00125	CbGpPWpGaD
Alprostadil—ABCC4—Hemostasis—HDAC2—chronic obstructive pulmonary disease	0.000165	0.00124	CbGpPWpGaD
Alprostadil—PTGIR—Hemostasis—NOS2—chronic obstructive pulmonary disease	0.000161	0.00121	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—PDE4A—chronic obstructive pulmonary disease	0.000159	0.0012	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—PDE4A—chronic obstructive pulmonary disease	0.000159	0.0012	CbGpPWpGaD
Alprostadil—PTGER2—Signaling by GPCR—HTR2A—chronic obstructive pulmonary disease	0.000157	0.00119	CbGpPWpGaD
Alprostadil—ABCC4—Platelet activation, signaling and aggregation—SERPINE1—chronic obstructive pulmonary disease	0.000156	0.00118	CbGpPWpGaD
Alprostadil—ABCC4—Platelet activation, signaling and aggregation—ALB—chronic obstructive pulmonary disease	0.000156	0.00118	CbGpPWpGaD
Alprostadil—Asthenia—Prednisone—chronic obstructive pulmonary disease	0.000156	0.000551	CcSEcCtD
Alprostadil—Pruritus—Prednisone—chronic obstructive pulmonary disease	0.000154	0.000543	CcSEcCtD
Alprostadil—PTGIR—GPCR downstream signaling—ADRB2—chronic obstructive pulmonary disease	0.00015	0.00113	CbGpPWpGaD
Alprostadil—PTGER1—GPCR downstream signaling—ADRB2—chronic obstructive pulmonary disease	0.00015	0.00113	CbGpPWpGaD
Alprostadil—Diarrhoea—Prednisone—chronic obstructive pulmonary disease	0.000149	0.000525	CcSEcCtD
Alprostadil—ABCC4—Hemostasis—PLAUR—chronic obstructive pulmonary disease	0.000148	0.00112	CbGpPWpGaD
Alprostadil—Dizziness—Prednisone—chronic obstructive pulmonary disease	0.000144	0.000508	CcSEcCtD
Alprostadil—PTGER2—Signaling Pathways—HDAC2—chronic obstructive pulmonary disease	0.000139	0.00105	CbGpPWpGaD
Alprostadil—ABCC4—NRF2 pathway—TGFB1—chronic obstructive pulmonary disease	0.000137	0.00104	CbGpPWpGaD
Alprostadil—Rash—Prednisone—chronic obstructive pulmonary disease	0.000137	0.000484	CcSEcCtD
Alprostadil—Dermatitis—Prednisone—chronic obstructive pulmonary disease	0.000137	0.000484	CcSEcCtD
Alprostadil—PTGIR—Signaling by GPCR—ADRB2—chronic obstructive pulmonary disease	0.000136	0.00103	CbGpPWpGaD
Alprostadil—PTGER1—Signaling by GPCR—ADRB2—chronic obstructive pulmonary disease	0.000136	0.00103	CbGpPWpGaD
Alprostadil—Headache—Prednisone—chronic obstructive pulmonary disease	0.000136	0.000481	CcSEcCtD
Alprostadil—PTGIR—Hemostasis—SERPINE1—chronic obstructive pulmonary disease	0.000135	0.00102	CbGpPWpGaD
Alprostadil—PTGIR—Hemostasis—ALB—chronic obstructive pulmonary disease	0.000135	0.00102	CbGpPWpGaD
Alprostadil—PTGIR—GPCR downstream signaling—EDN1—chronic obstructive pulmonary disease	0.000134	0.00101	CbGpPWpGaD
Alprostadil—PTGER1—GPCR downstream signaling—EDN1—chronic obstructive pulmonary disease	0.000134	0.00101	CbGpPWpGaD
Alprostadil—PTGIR—Hemostasis—NOS3—chronic obstructive pulmonary disease	0.000129	0.000973	CbGpPWpGaD
Alprostadil—Nausea—Prednisone—chronic obstructive pulmonary disease	0.000129	0.000456	CcSEcCtD
Alprostadil—PTGER2—Signaling Pathways—KL—chronic obstructive pulmonary disease	0.000129	0.000972	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—CXCR2—chronic obstructive pulmonary disease	0.000128	0.000966	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—CXCR2—chronic obstructive pulmonary disease	0.000128	0.000966	CbGpPWpGaD
Alprostadil—PTGIR—GPCR ligand binding—CXCL8—chronic obstructive pulmonary disease	0.000128	0.000965	CbGpPWpGaD
Alprostadil—PTGER1—GPCR ligand binding—CXCL8—chronic obstructive pulmonary disease	0.000128	0.000965	CbGpPWpGaD
Alprostadil—PTGER1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—chronic obstructive pulmonary disease	0.000128	0.000962	CbGpPWpGaD
Alprostadil—PTGIR—Signaling by GPCR—EDN1—chronic obstructive pulmonary disease	0.000122	0.000917	CbGpPWpGaD
Alprostadil—PTGER1—Signaling by GPCR—EDN1—chronic obstructive pulmonary disease	0.000122	0.000917	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—ADRB2—chronic obstructive pulmonary disease	0.000119	0.000897	CbGpPWpGaD
Alprostadil—PTGER1—GPCR downstream signaling—HTR2A—chronic obstructive pulmonary disease	0.000117	0.000883	CbGpPWpGaD
Alprostadil—PTGIR—GPCR downstream signaling—HTR2A—chronic obstructive pulmonary disease	0.000117	0.000883	CbGpPWpGaD
Alprostadil—ABCC4—Transmembrane transport of small molecules—HMOX1—chronic obstructive pulmonary disease	0.000116	0.000874	CbGpPWpGaD
Alprostadil—ABCC5—Disease—HDAC2—chronic obstructive pulmonary disease	0.000115	0.000867	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—GSTT1—chronic obstructive pulmonary disease	0.000115	0.000864	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—GCLC—chronic obstructive pulmonary disease	0.000113	0.000854	CbGpPWpGaD
Alprostadil—ABCC4—Platelet activation, signaling and aggregation—VEGFA—chronic obstructive pulmonary disease	0.000108	0.000811	CbGpPWpGaD
Alprostadil—PTGER2—GPCR downstream signaling—CXCL8—chronic obstructive pulmonary disease	0.000107	0.000808	CbGpPWpGaD
Alprostadil—ABCC5—Disease—KL—chronic obstructive pulmonary disease	0.000107	0.000806	CbGpPWpGaD
Alprostadil—PTGER1—Signaling by GPCR—HTR2A—chronic obstructive pulmonary disease	0.000106	0.000802	CbGpPWpGaD
Alprostadil—PTGIR—Signaling by GPCR—HTR2A—chronic obstructive pulmonary disease	0.000106	0.000802	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—EDN1—chronic obstructive pulmonary disease	0.000106	0.000802	CbGpPWpGaD
Alprostadil—ABCC4—Hemostasis—MMP1—chronic obstructive pulmonary disease	0.000106	0.0008	CbGpPWpGaD
Alprostadil—SLCO2B1—Transmembrane transport of small molecules—ALB—chronic obstructive pulmonary disease	0.000105	0.000792	CbGpPWpGaD
Alprostadil—ABCC4—Hemostasis—PLAU—chronic obstructive pulmonary disease	0.000104	0.000785	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—CTGF—chronic obstructive pulmonary disease	0.000103	0.00078	CbGpPWpGaD
Alprostadil—ABCC5—Transmembrane transport of small molecules—ALB—chronic obstructive pulmonary disease	0.0001	0.000757	CbGpPWpGaD
Alprostadil—ABCC4—Platelet activation, signaling and aggregation—TGFB1—chronic obstructive pulmonary disease	9.87e-05	0.000744	CbGpPWpGaD
Alprostadil—PTGER2—Signaling by GPCR—CXCL8—chronic obstructive pulmonary disease	9.73e-05	0.000733	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—ERBB3—chronic obstructive pulmonary disease	9.66e-05	0.000729	CbGpPWpGaD
Alprostadil—ABCC4—Hemostasis—NOS2—chronic obstructive pulmonary disease	9.57e-05	0.000722	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—CYP1A2—chronic obstructive pulmonary disease	9.52e-05	0.000718	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—HDAC2—chronic obstructive pulmonary disease	9.37e-05	0.000706	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—HDAC2—chronic obstructive pulmonary disease	9.37e-05	0.000706	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—HTR2A—chronic obstructive pulmonary disease	9.3e-05	0.000701	CbGpPWpGaD
Alprostadil—PTGIR—Hemostasis—VEGFA—chronic obstructive pulmonary disease	9.3e-05	0.000701	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—KL—chronic obstructive pulmonary disease	8.71e-05	0.000657	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—KL—chronic obstructive pulmonary disease	8.71e-05	0.000657	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—LEP—chronic obstructive pulmonary disease	8.65e-05	0.000652	CbGpPWpGaD
Alprostadil—PTGIR—Hemostasis—TGFB1—chronic obstructive pulmonary disease	8.53e-05	0.000644	CbGpPWpGaD
Alprostadil—ABCC4—Hemostasis—SERPINE1—chronic obstructive pulmonary disease	8.06e-05	0.000608	CbGpPWpGaD
Alprostadil—ABCC4—Hemostasis—ALB—chronic obstructive pulmonary disease	8.04e-05	0.000606	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—ADRB2—chronic obstructive pulmonary disease	8.04e-05	0.000606	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—ADRB2—chronic obstructive pulmonary disease	8.04e-05	0.000606	CbGpPWpGaD
Alprostadil—ABCC5—Disease—ERBB3—chronic obstructive pulmonary disease	8.02e-05	0.000604	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—GSTP1—chronic obstructive pulmonary disease	7.94e-05	0.000599	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—HMOX1—chronic obstructive pulmonary disease	7.83e-05	0.000591	CbGpPWpGaD
Alprostadil—ABCC4—Hemostasis—NOS3—chronic obstructive pulmonary disease	7.69e-05	0.00058	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—GSTM1—chronic obstructive pulmonary disease	7.3e-05	0.00055	CbGpPWpGaD
Alprostadil—PTGER1—GPCR downstream signaling—CXCL8—chronic obstructive pulmonary disease	7.23e-05	0.000546	CbGpPWpGaD
Alprostadil—PTGIR—GPCR downstream signaling—CXCL8—chronic obstructive pulmonary disease	7.23e-05	0.000546	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—EDN1—chronic obstructive pulmonary disease	7.18e-05	0.000541	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—EDN1—chronic obstructive pulmonary disease	7.18e-05	0.000541	CbGpPWpGaD
Alprostadil—PTGER2—Signaling by GPCR—EGFR—chronic obstructive pulmonary disease	7.11e-05	0.000536	CbGpPWpGaD
Alprostadil—PTGIR—Hemostasis—TP53—chronic obstructive pulmonary disease	7.03e-05	0.00053	CbGpPWpGaD
Alprostadil—ABCC4—Transmembrane transport of small molecules—ALB—chronic obstructive pulmonary disease	6.96e-05	0.000525	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—CYP1A1—chronic obstructive pulmonary disease	6.92e-05	0.000522	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	6.78e-05	0.000512	CbGpPWpGaD
Alprostadil—ABCC5—Disease—NOS2—chronic obstructive pulmonary disease	6.68e-05	0.000504	CbGpPWpGaD
Alprostadil—PTGER1—Signaling by GPCR—CXCL8—chronic obstructive pulmonary disease	6.57e-05	0.000495	CbGpPWpGaD
Alprostadil—PTGIR—Signaling by GPCR—CXCL8—chronic obstructive pulmonary disease	6.57e-05	0.000495	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—ERBB3—chronic obstructive pulmonary disease	6.53e-05	0.000492	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—ERBB3—chronic obstructive pulmonary disease	6.53e-05	0.000492	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	6.48e-05	0.000488	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—HTR2A—chronic obstructive pulmonary disease	6.28e-05	0.000474	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—HTR2A—chronic obstructive pulmonary disease	6.28e-05	0.000474	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—LEP—chronic obstructive pulmonary disease	5.84e-05	0.00044	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—LEP—chronic obstructive pulmonary disease	5.84e-05	0.00044	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	5.75e-05	0.000433	CbGpPWpGaD
Alprostadil—ABCC5—Disease—SERPINE1—chronic obstructive pulmonary disease	5.63e-05	0.000424	CbGpPWpGaD
Alprostadil—ABCC4—Hemostasis—VEGFA—chronic obstructive pulmonary disease	5.54e-05	0.000418	CbGpPWpGaD
Alprostadil—PTGER2—Signaling by GPCR—IL6—chronic obstructive pulmonary disease	5.46e-05	0.000412	CbGpPWpGaD
Alprostadil—ABCC5—Disease—NOS3—chronic obstructive pulmonary disease	5.37e-05	0.000405	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	5.2e-05	0.000392	CbGpPWpGaD
Alprostadil—ABCC4—Hemostasis—TGFB1—chronic obstructive pulmonary disease	5.09e-05	0.000384	CbGpPWpGaD
Alprostadil—PTGIR—Signaling by GPCR—EGFR—chronic obstructive pulmonary disease	4.8e-05	0.000362	CbGpPWpGaD
Alprostadil—PTGER1—Signaling by GPCR—EGFR—chronic obstructive pulmonary disease	4.8e-05	0.000362	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—ALB—chronic obstructive pulmonary disease	4.7e-05	0.000355	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	4.67e-05	0.000352	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	4.58e-05	0.000346	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	4.58e-05	0.000346	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—NOS3—chronic obstructive pulmonary disease	4.5e-05	0.000339	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	4.38e-05	0.00033	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	4.38e-05	0.00033	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	4.28e-05	0.000323	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	4.2e-05	0.000317	CbGpPWpGaD
Alprostadil—ABCC4—Hemostasis—TP53—chronic obstructive pulmonary disease	4.19e-05	0.000316	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	3.88e-05	0.000293	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	3.88e-05	0.000293	CbGpPWpGaD
Alprostadil—PTGIR—Signaling by GPCR—IL6—chronic obstructive pulmonary disease	3.69e-05	0.000278	CbGpPWpGaD
Alprostadil—PTGER1—Signaling by GPCR—IL6—chronic obstructive pulmonary disease	3.69e-05	0.000278	CbGpPWpGaD
Alprostadil—ABCC5—Disease—TGFB1—chronic obstructive pulmonary disease	3.55e-05	0.000268	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—TP53—chronic obstructive pulmonary disease	3.53e-05	0.000266	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	3.51e-05	0.000265	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	3.51e-05	0.000265	CbGpPWpGaD
Alprostadil—ABCC5—Disease—EGFR—chronic obstructive pulmonary disease	3.48e-05	0.000263	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—IL6—chronic obstructive pulmonary disease	3.23e-05	0.000243	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	3.15e-05	0.000238	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	3.15e-05	0.000238	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	2.89e-05	0.000218	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	2.89e-05	0.000218	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	2.84e-05	0.000214	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	2.84e-05	0.000214	CbGpPWpGaD
Alprostadil—ABCC5—Disease—IL6—chronic obstructive pulmonary disease	2.68e-05	0.000202	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—TP53—chronic obstructive pulmonary disease	2.38e-05	0.00018	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—TP53—chronic obstructive pulmonary disease	2.38e-05	0.00018	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—IL6—chronic obstructive pulmonary disease	2.18e-05	0.000164	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—IL6—chronic obstructive pulmonary disease	2.18e-05	0.000164	CbGpPWpGaD
